NASDAQ$IVVD
Invivyd Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Invivyd reported an increase in PEMGARDA net product revenue and progress in clinical trials.
Invivyd reported $9.3 million in PEMGARDA net product revenue for Q3 2024, an increase from $2.3 million in Q2 2024. The company ended the quarter with $106.9 million in cash and cash equivalents and is targeting near-term profitability. They highlight the updated PEMGARDA Fact Sheet and the initiation of dosing in the Phase 1 clinical trial of VYD2311.
- PEMGARDA net product revenue reached $9.3 million in Q3 2024.
- Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalents.
- The company aims for near-term profitability, targeting the first half of 2025.
- Dosing began in the Phase 1 clinical trial of VYD2311 in August 2024.
Headline financials
Revenue & EPS history
Invivyd · Revenue · Quarterly
$9.3M
Forward guidance
Invivyd expects to end 2024 with at least $65 million in cash and cash equivalents, based on anticipated growth of net product revenue and various operational efficiency improvements.
Tailwinds
- Anticipated growth of net product revenue
- Operational efficiency improvements
- Focus on commercial execution to drive revenue growth and market expansion
- Confidence in growth potential for PEMGARDA with updated Fact Sheet
- Potential of PEMGARDA to address unmet need of COVID-19 pre-exposure prophylaxis
Headwinds
- Uncertainties regarding market acceptance and future sales of PEMGARDA
- Dependence on continued EUA for PEMGARDA
- Potential negative impacts from virologic activity data questioning pemivibart's neutralization
- Risk of failing to maintain acceptable safety, tolerability and efficacy
- Uncertainties regarding regulatory authorization or approval process
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-1.7%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-16.8%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+18.4%
Q4 2021
Best reaction
-21.6%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -21.6% | -30.4% | -48.5% | |
| Q4 2025 | +2.4% | +7.0% | -25.1% | |
| Q3 2025 | +1.3% | +8.6% | +46.7% | |
| Q1 2025 | -15.8% | -3.2% | -5.3% | |
| Q4 2024 | +2.6% | -8.3% | -29.2% | |
| Q3 2024 | -15.2% | -13.8% | -38.5% | |
| Q2 2024 | -1.9% | -13.9% | +8.5% | |
| Q1 2024 | -10.7% | -4.0% | -33.2% | |
| Q4 2023 | +6.3% | +1.8% | -49.8% | |
| Q3 2023 | -7.9% | -1.3% | +11.8% | |
| Q2 2023 | +2.6% | +5.1% | +13.5% | |
| Q1 2023 | +1.4% | +5.6% | -8.5% | |
| Q4 2022 | -7.7% | -4.9% | -19.0% | |
| Q3 2022 | +8.8% | +6.3% | -40.2% | |
| Q2 2022 | -2.5% | +5.3% | +9.8% | |
| Q1 2022 | +7.9% | +10.9% | +11.3% | |
| Q4 2021 | +18.4% | +13.8% | -25.7% | |
| Q3 2021 | +5.5% | +4.9% | -66.8% | |
| Q2 2021 | -7.0% | -15.0% | -30.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro